European journal of radiology · 2025
Longitudinal fluctuations in reported background parenchymal enhancement on contrast enhanced mammography.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nissan Noam, Reiner Jeffrey S, Arita Yuki, Amir Tali, Mango Victoria L, Fruchtman-Brot Hila, Ochoa Albiztegui Rosa Elena, Gluskin Jill, Feigin Kimberly, Jochelson Maxine S, Sung Janice S
Аннотация
OBJECTIVES: Background parenchymal enhancement (BPE) and mammographic density (MD) are imaging biomarkers derived from contrast-enhanced mammography (CEM). However, unlike MD, the consistency of BPE across consecutive examinations in pre- and postmenopausal women has remained unexplored.
MATERIALS AND METHODS: A computational search was conducted for all screening CEM exams performed at our facility between December-2012 and January-2024 to identify patients with at least five consecutive negative annual screenings. BPE grades and MD categories were extracted from the official radiology reports, and their variability parameters were statistically compared both between these factors and across age groups.
RESULTS: Forty-five eligible patients at premenopausal age-group were identified (mean age at first scan 38.2 ± 3.4 years, range: 27-42) and a matched postmenopausal age-group was assembled (mean age at first scan 63.7 ± 3.8 years, range: 60-74), resulting in 450 CEMs analyzed. BPE demonstrated greater variability than MD, including fluctuations of at least one category on the scale (71.1-91.1 %), two-category changes (17.8-22.2 %), and transitions between low and high binary categories (17.8-27.7 %) (P < 0.01 for all). Similar rates of two-category BPE transitions (P = 0.65) and shifts between low and high binary categories (P = 0.32) were observed in pre- and postmenopausal women; however, the latter group had a significantly smaller proportion of cases with five consistent grades (P = 0.02).
CONCLUSION: BPE on CEM demonstrates greater longitudinal variability than MD across all age groups and is not more pronounced in premenopausal compared to postmenopausal women. This highlights its dynamic nature and underscores the need for caution when considering BPE in clinical decision-making or as a biomarker, while also suggesting that strict menstrual cycle phase targeting may be less critical.
MATERIALS AND METHODS: A computational search was conducted for all screening CEM exams performed at our facility between December-2012 and January-2024 to identify patients with at least five consecutive negative annual screenings. BPE grades and MD categories were extracted from the official radiology reports, and their variability parameters were statistically compared both between these factors and across age groups.
RESULTS: Forty-five eligible patients at premenopausal age-group were identified (mean age at first scan 38.2 ± 3.4 years, range: 27-42) and a matched postmenopausal age-group was assembled (mean age at first scan 63.7 ± 3.8 years, range: 60-74), resulting in 450 CEMs analyzed. BPE demonstrated greater variability than MD, including fluctuations of at least one category on the scale (71.1-91.1 %), two-category changes (17.8-22.2 %), and transitions between low and high binary categories (17.8-27.7 %) (P < 0.01 for all). Similar rates of two-category BPE transitions (P = 0.65) and shifts between low and high binary categories (P = 0.32) were observed in pre- and postmenopausal women; however, the latter group had a significantly smaller proportion of cases with five consistent grades (P = 0.02).
CONCLUSION: BPE on CEM demonstrates greater longitudinal variability than MD across all age groups and is not more pronounced in premenopausal compared to postmenopausal women. This highlights its dynamic nature and underscores the need for caution when considering BPE in clinical decision-making or as a biomarker, while also suggesting that strict menstrual cycle phase targeting may be less critical.